New COVID-19 drug passes phase 2 clinical trial
The new treatment, developed by Avalo Therapeutics with Sanford Burnham Prebys researchers, can mitigate lung damage and improve survival in COVID patients.
Unlike other experimental COVID therapies, CERC-002 does not target the virus itself, instead targeting the immune response associated with the virus to stop the disease from progressing before it becomes fatal.
“We have made a lot of progress in controlling the pandemic with vaccines and other new therapies, but it’s not over yet,” says Carl Ware, Ph.D., director of the Infectious and Inflammatory Disease Center at Sanford Burnham Prebys. “Treatments like this may bring physicians an option to protect infected people from severe illness."